Galderma Group AG

GALD

CH1335392721

Personal Products

Market Closed - Swiss Exchange Other stock markets 11:31:41 2025-07-08 am EDT			5-day change	1st Jan Change
124.50 ^CHF	+2.64%		+7.79%	+23.71%

Jul. 01	Galderma's Finance Chief to Leave	MT
Jul. 01	Galderma Group AG Announces Departure of Thomas Dittrich as Chief Financial Officer	CI

Galderma's Atopic Dermatitis Drug Gets Backing for Routine NHS Funding

Published on 06/12/2025 at 09:16

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Galderma Group AG

Galderma's Finance Chief to Leave	Jul. 01	MT
Galderma Group AG Announces Departure of Thomas Dittrich as Chief Financial Officer	Jul. 01	CI
Swiss Market Index Retreats; Galderma Shares Rise	Jun. 25	MT
Galderma Initiates Phase 2 Trials to Evaluate Systemic Sclerosis, Chronic Pruritus Treatment	Jun. 25	MT
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients with Systemic Sclerosis and Chronic Pruritus of unknown Origin	Jun. 25	CI
Galderma Group AG(SWX:GALD) added to S&P International 700	Jun. 22	CI
Galderma Group AG(SWX:GALD) added to S&P EUROPE 350 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)	Jun. 22	CI
Galderma Group AG(SWX:GALD) added to S&P EUROPE 350 - Health Care	Jun. 22	CI
Galderma Group AG(SWX:GALD) added to S&P EUROPE 350	Jun. 22	CI
Galderma Group AG(SWX:GALD) added to S&P Global 1200	Jun. 22	CI
Galderma Announces Data from New Interim Analysis of Study Investigating the Long-Term Safety and Efficacy of Nemluvio in Moderate-To-Severe Prurigo Nodularis	Jun. 18	CI
Galderma Group AG - New Data Demonstrate Nemluvio®'S (Nemolizumab) Favorable Safety Profile	Jun. 18	RE
Galderma Publishes New Data On Nemluvio's Safety Profile	Jun. 18	RE
Swiss stocks - Factors to watch on June 18	Jun. 18	RE
Galderma Establishes New U.S. Headquarters In Miami	Jun. 17	RE
Galderma Establishes New U.S. Headquarters in Miami and Strengthens Regional Leadership	Jun. 17	CI
Galderma?S Nemluvio® (Nemolizumab) Receives National Institute for Health and Care Excellence Recommendation for Moderate-To-Severe Atopic Dermatitis in England and Wales	Jun. 12	CI
Galderma's Atopic Dermatitis Drug Gets Backing for Routine NHS Funding	Jun. 12	MT
Galderma Announces Two-Year Data from A New Interim Analysis of A Long-Term Extension Study Investigating the Safety and Efficacy of Nemluvio in Moderate-To-Severe Atopic Dermatitis	Jun. 06	CI
Galderma Says Long-Term Data On Nemluvio (Nemolizumab) Demonstrate Its Favorable Safety Profile	Jun. 06	RE
Swiss stocks - Factors to watch on June 6	Jun. 06	RE
EQT sells shares in German company Galderma	Jun. 04
EQT Wraps Up CHF1.86 Billion Sale of Galderma Shares	Jun. 03	MT
EQT Completes Sale Of Shares In Galderma	Jun. 03	RE
Galderma Group AG's Equity Buyback announced on May 28, 2025, has expired.	Jun. 01	CI

Galderma Group AG is a Switzerland based holding Company, specializing in dermatological treatments and skin care products. The Company, throw its subsidiaries, operates a portfolio of carious self-care brands focusing primarily on dermatological solutions, through its subsidiaries. production within the portfolio include neuromodulators, fillers. and biostimulators. these products are designed to relax winkles via injection, fill wrinkles in a specific location via injection and stimulate the body's cells to function optimally. The production process, for the various products primarily takes place in house, form research and development to manufacturing. In addition, including education, scientific engagements, and other services are offered.

Employees

Sector

Personal Products

Calendar

Jul. 23 - Q2 2025 Earnings Release

More about the company